Anti-inflammatory agent 2

LTB4-IN-1 (Anti-inflammatory agent 2) with IC50 of 70 nM is an inhibitor of leukotriene synthesis (LTB4).

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Anti-Influenza agent 4 is a potent and selective inhibitor of the influenza virus, effectively inhibiting the A Parma and A Roma strains with EC50s of 62 nM and 150 nM, respectively.

Anti-TB agent 1 is a potent and orally active anti-tuberculosis compound (MICs: < 2 nM against the Mtb strains H37Rv, rRMP, and rINH).

Anti-Inflammatory Peptide 1 Acetate (C45H82N12O14S2) possesses a potent anti-inflammatory activity in vivo and is a strong inhibitor of phospholipase A2 (PLA2), whose increased presence and activity results in inflammation and pain at certain bodily sites

Antitrypanosomal agent 2 shows potent and specific antiparasite activities against Trypanosoma brucei.

Anti-inflammatory agent 49 is a potent inhibitor of Drp1-Fis1 interaction, inhibits GTPase, and can be used in the study of diseases caused by mitochondrial dysfunction.

Anticonvulsant agent 2 is a potent, orally active anticonvulsant demonstrating antiepileptic activity in a drug-resistant epilepsy model.

Anti-inflammatory agent 35 is a potent anti-inflammatory agent.

Anti-inflammatory agent 36 is an anti-inflammatory agent that exhibited dose-dependent inhibition of LPS-induced release of TNF-a and IL-6 in active RAW 264.7 mouse macrophages (IC50 = 3.69 μM and 3.68 μM, respectively).

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Anti-inflammatory agent 52 (compound 7c) is an orally active, selective COX-2 inhibitor with demonstrated anti-HT29 metastatic activity, causing periodic arrest in the S phase and G2 M phase. This agent exhibits moderate anti-inflammatory efficacy alongside a notable safety profile. Additionally, it possesses the uncommon capability of inhibiting tumor development in a mouse model, indicative of anti-cancer properties [1].

Anti-inflammatory agent 8 (compound 13), designated as an anti-inflammatory agent 8, displays enhanced activity on the COX-2 enzyme compared to COX-1, with an IC50 value of 0.09 nM, and exhibits oral bioavailability [1].

Anti-inflammatory agent 56 (Compound 9), a selective COX-2 inhibitor with an IC50 of 0.54 μM, exhibits antioxidant and anti-inflammatory properties by inhibiting oxidative stress-induced cell death and neuroinflammation through the suppression of Keap1, COX-2, and iNOS. It demonstrates low acute toxicity in mice with an LD50 of 1000 mg kg [1].

Anti-inflammatory agent 80, an anti-inflammatory and anti-tumor compound, can be isolated from Cynanchum limprichtii Schltr [1] [2].

Anti-inflammatory agent 52 (compound 7j) is an orally active, selective COX-2 inhibitor that induces G2 M phase arrest and exhibits anti-HT29 transfer activity. It demonstrates moderate anti-inflammatory efficacy and a notable safety profile, and uniquely inhibits tumor growth in mouse models, indicative of its anticancer properties [1].

Anti-inflammatory agent 33, a potent p38α inhibitor, effectively reduces NO production and suppresses LPS-induced expression of iNOS, COX-2, p-p38α, and p-MK2 proteins, thereby demonstrating anti-inflammatory activity.

Anti-inflammatory agent 5 effectively inhibits nitric oxide (NO) production in lipopolysaccharide-induced BV-2 microglial cells.

Anti-inflammatory agent 9 (compound 28) is a benzimidazothiazole derivative derived from tilomisole, exhibiting higher COX-2 enzyme affinity than COX-1, thereby demonstrating promising anti-inflammatory properties and oral bioavailability [1].

The anti-inflammatory agent 41 (13a) markedly inhibits lipopolysaccharide (LPS)-induced expression of the proinflammatory cytokines IL-6 and TNF-α in J774A.1, THP-1, and LX-2 cells, while also preventing the activation of the NF-κB pathway [1].

Anti-inflammatory agent 10 is a tilomisole-based benzimidazole-thiazole derivative that is orally active. anti-inflammatory agent 10 is more active against COX-2 enzymes than COX-1.

Anti-inflammatory agent 31 (enone 17), an andrographolide derivative, inhibits NF-κB activation by blocking the PI3K Akt and ERK1 2 MAPK pathways. It effectively restores intracellular GSH levels and exhibits protective effects on the liver [1].

Anti-inflammatory agent 14 (compound 28) exhibits a MIC50 of 2 μM for Mtb H37Rv and also functions as an anti-inflammatory agent [1].

Compound 13, also known as Anti-inflammatory agent 57 and classified as a pyranocoumarin, is a natural product extracted from the roots of Peucedanum praeruptorum. This compound possesses both multidrug-resistance (MDR) reversal properties and anti-inflammatory effects [1].

Anti-aging agent 1 (compound 24), a piperlongumine (PL) derivative, demonstrates a significant enhancement in senolytic activity, being 50 times more effective against senescent WI-38 fibroblasts than PL [1].

Compound 2v (Anti-inflammatory agent 45) demonstrates anticancer properties with direct inhibitory impacts on the proliferation of various blood malignancies, such as leukemia, lymphoma, and myeloma cell lines. It induces apoptosis and suppresses nitric oxide production in HL60 leukemia cells (IC50 = 14.7 μM) [1].

Compound 56 (Antidiabetic agent 2) is a glucose-uptake promoter that inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase, with IC50 values of 0.036, 0.042, 0.241, and 0.185 μM, respectively. This agent effectively decreases blood glucose levels [1].

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

Analgesic Agent-2, a selective orally active inhibitor of the NaV1.8 channel, demonstrates an IC50 of 50.18 nM in HEK293 cells that stably express the human NaV1.8 channel, indicating its potential for analgesic activity [1].

Anti-Trypanosoma cruzi agent-1 (Compd E5) demonstrates a potent anti-Toxoplasma effect.

Anti-neurodegeneration agent 1, a neurodegeneration-targeting agent.

Anti-inflammatory agent 22 (compound 14a) is a potent orally active compound with anti-inflammatory properties, effectively inhibiting LPS-induced TNF-α production with an IC50 of 14.6 μM. Additionally, Anti-inflammatory agent 22 prevents adipogenesis and effectively suppresses limb lymphedema volume in mice, holding promise for treating inflammation-related conditions, particularly lymphedematous tissue disorders [1].

Anti-Trypanosoma cruzi Agent-4 is a Trypanosoma cruzi inhibitor utilized for the investigation of infections caused by this parasite.

Anti-MRSA agent 4 (compound 7a), a selective and potent inhibitor of Gram-positive Methicillin-resistant Staphylococcus aureus (MRSA) growth, demonstrates a minimum inhibitory concentration (MIC) of ≤ 0.26 µM and exhibits neither cytotoxic nor hemolytic activity in HEK293 cells [1].

Anti-MRSA agent 2 (compound 14) is a potent inhibitor of methicillin-resistant Staphylococcus aureus (MRSA) (MIC: 0.098 μg ml), exhibiting relatively low toxicity to normal cells. It strongly disrupts bacterial membranes and effectively binds to bacterial genomic DNA.

Antiplatelet agent 2 is a ticagrelor analogue that exhibits anti-platelet effects and can be used in platelet agglutination studies.

Anti-MRSA agent 7 (Compound 12) is a potent antibacterial compound that effectively inhibits S. aureus and E. coli DNA gyrases, as well as topo IV enzymes from the same organisms, with IC50 values of 0.185 μM, 0.365 μM, 0.341 μM, and 0.059 μM, respectively [1].

Anti-MRSA agent 1 is an MRSA inhibitor with an MIC value of 0.5 μg/mL and is effective in alleviating the effects of MRSA resistance.

Anti-melanoma agent 1 (Compound 5m) is an apoptotic inducer in melanoma cells.

Anti-MRSA agent 3 inhibits methicillin-resistant Staphylococcus aureus (MRSA) activity significantly (MIC: 0.098 μg/ml) with low toxicity to normal cells. anti-MRSA agent 3 has a high binding affinity for bacterial genomic DNA and a strong ability to disrupt bacterial cell walls and membranes.

Anti-TSWV agent 1 is a highly effective inactivator (EC50:144 μg/mL) of tomato spotted wilt virus (TSWV).

Anti-Aβ agent 1A is a potent anti-amyloid-β agent. Anti-Aβ agent 1A significantly inhibits LPS-induced IL-1β, IL-6 and TNF-α levels and reduces H2O2-induced apoptosis in SH-SY5Y cells using the mitochondrial pathway, exhibiting antioxidant, anti-inflammatory, anti-Aβ toxicity and neuroprotective activities. Anti-Aβ agent 1A can be used to study Alzheimer's disease.

Anti-osteoporosis agent-1 (comp 4aa) is a potent RPA (replication protein A) inhibitor with an IC50 value of 18 μM [1].

Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody produced from CHO cells, which specifically targets the S1 domain of the Spike protein in both SARS-CoV and SARS-CoV-2.

Compound 29 (Compound 7) is an anti-inflammatory agent that exhibits hepatoprotective activity [1].

Compound 5b (Anti-inflammatory agent 61) is a potent anti-inflammatory agent that diminishes TNF-α expression in LPS-induced inflammation within RAW 264.7 cells and mitigates APAP-induced inflammation in HepG2 cells [1].

Anti-inflammatory agent 62 mitigates acetaminophen-induced hepatotoxicity in HepG2 cells by modulating inflammatory and oxidative stress pathways [1].

Anti-Mouse TCR V gamma 2 Antibody is an inhibitory IgG antibody derived from Armenian Hamster, targeting mouse TCR V gamma 2.